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Purpose: Concurrent chemoradiotherapy has become the standard 
treatment for unresectable locally advanced non-small cell lung cancer 
(NSCLC). However, distant metastases remain the major site of failure. 
Here we report a randomized phase II trial of consolidation chemother-
apy with monthly paclitaxel and cisplatin (PC) or observation after con-
current chemoradiotherapy in patients with locally advanced NSCLC to 
evaluate the feasibility and the role of consolidation chemotherapy.
Methods: Between March 2000 and August 2002, a total of 104 
unresectable stage III NSCLC patients who showed at least minimal 
response (6 complete, 86 partial, and 12 minimal responses) after 
concurrent chemoradiotherapy were randomized to receive 3 cycles of 
consolidation chemotherapy (n=50) or to be observed (n=54). Con-
current chemoradiotherapy consisted of weekly paclitaxel 40 mg/m2 
and cisplatin 20 mg/m2 plus thoracic radiation (total dose of 70.2 Gy). 
Consolidation chemotherapy with paclitaxel 135 mg/m2 and cisplatin 
60 mg/m2 started 4 weeks after completion of concurrent chemoradio-
therapy and repeated every 4 weeks. 
Results: With a median follow-up of 41 months, there were no signiﬁ-
cant differences in progression-free survival (PFS) and overall survival 
(OS) between consolidation and observation groups (median PFS, 13 
vs. 12 months; median OS, 19 vs. 24 months). During consolidation 
PC, grade 3 or 4 neutropenia was observed in 29% of the patients. 
However, there was no episode of febrile neutropenia. 
Conclusions: Consolidation chemotherapy with monthly PC after con-
current chemoradiotherapy is feasible and generally tolerable, however, 
does not show a survival beneﬁt in locally advanced
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Background: Some papers report that tumor volume is a signiﬁcant 
prognostic factor in thoracic radiotherapy for non-small-cell lung can-
cer (NSCLC) patients. The purpose of this study is to investigate and 
conﬁrm the impact of total tumor volume(TTV) on survival in patients 
with stage III NSCLC treated with thoracic radiotherapy and concur-
rent chemotherapy.
Methods: From prospectively maintained database of our department, 
sixty patients were identiﬁed who underwent thoracic radiotherapy 
and concurrent chemotherapy in stage III NSCLC patients with an age 
under 75 year between October 2002 and December 2005. All patients 
underwent a CT scanning to facilitate treatment planning. TTV were 
calculated by the three-dimensional radiotherapy planning system. The 
median follow-up duration was 21 months in surviving patients. The 
Kaplan-Meier method, the log rank test and the Cox proportional haz-
ard model were used for evaluation of survival. Survival was updated 
on March 1,2007.
Results: The patients consisted of 47 males and 13 females in gender, 
64 year old of median age (range 44-75), 27 IIIA and 33 IIIB in TNM 
staging, 24 squamous cell carcinoma, 30 adenocarcinoma and 6 oth-
ers in histology and 39 PS 0, 19 PS1, 2 PS2 in performance status, 
respectively. TTV was ranged between 11 and 1512 cc (median 78.5 
cc). A prescribed dose of radiotherapy was 60 Gy in 30 fractions using 
4-,6- or 10-MV X-rays in all patients. Chemotherapy regimens were 
as follows: 1) weekly paclitaxel (TXL)+ weekly carboplatin(CBDCA) 
consolidation CBDCA + TXLx2 in 33 patients, 2) mitomycin C + vin-
desine+ cisplatin x 4 in 12, 3)cisplatin+vinorelbinex4 in 8 and 4)others 
in 7. The overall 2-year survival rate was 66 %. In patients with larger 
TTV than median TTV 78.5 cc and with smaller TTV, the overall 2-
year survival rates were 52% and 80%, respectively. The median over-
all survival was 29 months. The median overall survival with smaller 
TTV is not mature enough to be evaluated. On univariate analysis, 
stage IIIA was signiﬁcantly better prognostic factor than IIIB (P=0.042) 
and the survival with smaller TTV tends to be favorable (P=0.056). PS 
(P=0.908) and gender (P=0.356) were not signiﬁcant. On multivari-
ate analysis, there was tendency of favorable survival in smaller TTV 
(P=0.068) and others (stage, PS, gender) were not signiﬁcant.
Conclusion: TTV is an independent prognostic factor in stage III 
NSCLC treated with concurrent chemoradiotherapy.
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Background: The optimal duration of chemotherapy for advanced 
non-small cell lung cancer (NSCLC) is unclear. We performed a sys-
tematic review and meta-analysis of published randomized controlled 
trials (RCT) comparing longer versus shorter durations of chemo-
therapy. 
Methods: We searched MEDLINE, EMBASE and CENTRAL for 
RCTs comparing 1) a deﬁned number of cycles of chemotherapy versus 
continuing until disease progression, 2) a deﬁned number of cycles 
versus a higher number of cycles of the same chemotherapy and, 3) a 
deﬁned number of cycles of initial chemotherapy vs the same initial 
chemotherapy followed by additional cycles of a different chemo-
therapy. The primary outcome was overall survival (OS). Secondary 
outcomes included progression-free survival (PFS), adverse events 
(AE), and quality of life (QL). Hazard ratios (HR), conﬁdence intervals 
(CI) and p-values (p) were estimated with ﬁxed effects models using 
Revman 4.2.8
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Results: We found 10 RCTs including 1575 patients. Longer dura-
tions of chemotherapy prolonged PFS (HR 0.83, 95% CI 0.75 to 0.93, 
p=0.0007) but not OS (HR 0.96, 95%CI 0.87 to 1.05, p=0.3). The 
results were comparable among the different trials, designs and drugs 
(heterogeneity p>0.3) and were unaffected by excluding the 3 trials of 
lowest quality. AE were more frequent with longer durations of chemo-
therapy. QL was assessed in 5 trials with variable results. 
Conclusions: Continuing chemotherapy for more than 3 or 4 cycles 
delayed disease progression, increased adverse events, and may have 
impaired quality of life, but did not improve overall survival. These 
ﬁndings raise doubts about the value of continuing chemotherapy 
beyond 4 cycles in NSCLC.
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Background: S-1 is an oral anticancer drug combining tegafur, oxonic 
acid, and CDHP. We have conducted a phase II trial to evaluate the 
efﬁcacy and toxicity of irinotecan in combination with S-1 for patients 
with advanced NSCLC. 
Method: Chemotherapy-naïve pts with advanced stage (IIIB/IV) 
NSCLC, ECOG PS of 0-1, and adequate organ functions were treated 
with i.v. irinotecan 150 mg/m2 on day 1 and oral S-1 80 mg/m2/day on 
days 1 to 14 every 3 weeks. The primary objective of this study was to 
determine the objective response rate. With the target activity level of 
35% and the lowest response rate of interest set at 20%, 50 eligible pa-
tients were required with an 80% power to accept the hypothesis and a 
5% signiﬁcance level to reject the hypothesis. Allowing for a 10% loss 
to follow-up rate, a total of 55 patients were planned to enroll. 
Results: Fifty-six patients were enrolled between February 2006 and 
June 2006 and received a total of 255 treatment cycles (median 4; 
range, 1-12). No complete response and 16 partial responses were 
observed for an overall response rate of 28.6%. Twenty-four patients 
(42.9%) had stable disease and twelve patients (21.4%) had progress 
disease as best response. The tumor control rate (partial response + 
stable disease) was 71.4%. Survival data and detail toxicity proﬁles will 
be presented at the meeting. 
Conclusion: The combination of irinotecan/S-1 is well tolerated, can 
be used for outpatients, and is active for the treatment of advanced 
NSCLC. This treatment merits further comparison with other platinum-
based combinations.
PD4-2-3 Cytotoxic Chemotherapy I, Tue, 16:00 - 17:30
Global Lung Oncology Branch trial 3 (Glob 3): final results 
of a randomised multinational Phase III study of oral and i.v. 
vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) 
plus CDDP as first-line treatment for advanced Non-Small Cell 
Lung Cancer (NSCLC)
Tan, Eng-Huat1 Grodzki, Tomasz2 Schneider, Claus-Peter3 Zatloukal, 
Peter4 Reck, Martin5 Aitini, Enrico6 Rolski, Janusz7 
1 National Cancer Center, Singapore, 2 Regional Hospital For Lung 
Diseases, Szczecin, Poland 3 Central Clinic Bad Berka, Bad Berka, 
Germany 4 Pneumology Clinic, Prague, Czech Republic 5 Krankenhaus 
Grosshansdorf, Grosshansdorf, Germany 6 Hospital Carlo Poma, Man-
tova, Italy 7 Centre of Oncology Maria Sklodowska Curie Memorial 
Institute, Krakow, Poland 
Background: Intravenous weekly NVB (NVBiv) and CDDP (NC) 
represents one of the reference treatments for advanced NSCLC. An 
oral formulation of NVB (NVBo) has been approved in NSCLC with 
similar efﬁcacy as NVBiv. GLOB3 compared, in histologically con-
ﬁrmed advanced NSCLC chemonaïve patients (age 18-75 years; KPS 
80-100%), NVBiv D1 and NVBo D8 versus DTX in a CDDP-based 
combination (DC) as time to treatment failure (TTF), overall response 
(OR), progression-free survival (PFS), overall survival (OS) and toler-
ance (NCI-CTC v2 criteria).
Methods: An estimated sample size of 350 patients (386 to accom-
modate an anticipated 10% loss of follow-up) was required (type I error 
5%, power 80%, two-sided Log-rank test adjusted on stage), assuming 
a median TTF NC/DC 3.8/2.8 months, and an accrual time 24 months. 
Patients randomly received: CDDP 80 mg/m2 with NVBiv 30 mg/m2 
D1 and NVBo 80 mg/m2 D8 every 3 weeks, after a 1st cycle at NVBiv 
25 mg/m2 D1 and NVBo 60 mg/m2 D8 (dose escalated in absence of 
grade 3/4 neutropenia), or CDDP 75 mg/m2 and DTX 75 mg/m2 D1 
every 3 weeks, for a maximum of 6 cycles in both arms.
Results: Between 09.02.2004 and 10.01.2006, 390 patients (NC/DC: 
194/196) were randomised and 381 (190/191) were treated. Disease 
extension at study entry (%): unresectable locoregional 20.5/15.2, 
metastatic 79.5/84.8, patients with ≥ 3 organs involved 45.3/40.8. 
Median age: 59.4/62.1 years. Male: 139/146. Squamous (%): 34.2/33.5, 
Adenocarcinoma 41.6/39.3. Mean number of cycles: NC 4.2 ± 1.8, DC 
4.4 ± 1.9. Median Relative DI (%): NVB 92, DTX 96.3. NVBiv and 
NVBo dose escalation at Cycle 2: 71%. Median TTF (months), ITT 
analysis (median follow-up 18 months) [95% CI]: NC 3.2 [NC 2.9-4.2], 
DC 4.1 [3.4-4.5] (p= 0.19). Overall Response (RECIST) [95% CI] (ITT 
after panel review): NC 27.4% [21.2-34.2], DC 27.2% [21.0-34.2]. Me-
dian PFS (months) [95% CI]: NC 4.9 [4.4-5.9], DC 5.0 [4.3-6.1] (p= 
0.98). Median OS (months) [95% CI]: NC 9.9 [8.6-11.6], DC 9.8 [8.8-
11.5] (p= 0.66). G 3/4 haematological toxicity (number of cycles: NC 
807, DC 845): neutropenia NC 23.3%; DC 28.2%; thrombopenia: NC 
0.9%, DC 0.1%; haemoglobin: NC 4.7%, DC 1.2%; febrile neutropenia 
(Pizzo’s deﬁnition, % patients): NC 10.5, DC 5.2. Non haematological 
toxicity (% of patients): G1/2 alopecia: NC 35.3%, DC 58.1%. G3/4 
fatigue: NC 5.8%, DC 6.3%. G3/4 diarrhoea: NC 2.1%, DC 5.8%. G3/4 
constipation: NC 0.5%, DC 1%. G3/4 sensory neuropathy: NC 0.5%, 
DC 0%.
Conclusions: NVB oral offers opportunities to optimise D1, D8 NC 
regimen. NVB and CDDP achieves similar efﬁcacy as DC in terms of 
TTF, OR, TTP and OS with similar and acceptable tolerance as front-
line chemotherapy for advanced NSCLC patients.
